Chemotherapy 101 for Radiation Oncology Workers

Similar documents
Acute Lymphocytic Leukemia

Medication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC

Formulary Chemotherapy Agents: (Current as of 6/2018) Therapeutic Class

ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School

MEDICAL NECESSITY GUIDELINE

Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data

To help doctors give their patients the best possible care, the American

HCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1

DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days

Introduction to Antineoplastic Prescribing

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

Form 2023 R2.0: Ovarian Cancer Pre-HSCT Data

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

Overview of Cancer. Laura Bingell RN Transition Center Nurse for MFP (607)

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249


Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded

Bladder Cancer (Urothelial) Pathways

through the cell cycle. However, how we administer drugs also depends on the combinations that we give and the doses that we give.

Adjuvant Systemic Therapy in Early Stage Breast Cancer

2. Mitotic Spindle Inhibitors (modulators of tubulin polymerisation) 3. Antimetabolites (anti-folates, pyrimidine and purine analogues)

Committee Approval Date: December 12, 2014 Next Review Date: July 2015

SCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders

DRUG PROPERTIES YOU NEED TO KNOW

Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites.

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION

Haematology, Oncology and Palliative Care Directorate.

Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site

Bladder Cancer Pathways (Urothelial)

DRUG PROPERTIES YOU NEED TO KNOW

1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.

Hazard Meds: Navigating the Warning Beacons

New Developments in Cancer Treatment. Dulcinea Quintana, MD

BLOOD AND LYMPH CANCERS

Ovarian Cancer. compendia TREATMENT OF

Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and

MASCC Guidelines for Antiemetic control: An update

Description The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )

Cancer Chemotherapy. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center

ALKYLATING AGENTS (22)

FREEDOM OF INFORMATION SOUTH EAST SCOTLAND CANCER NETWORK

Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy

Part III: Anticancer Agents Antibiotics

Objectives. Principles of Cancer Treatment. Cancer Treatment Modalities. Cancer Treatment Modalities

COST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!!

See Important Reminder at the end of this policy for important regulatory and legal information.

Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting

AD regimen, 576 adrenal steroid inhibitor. aminoglutethimide, 23 25

Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A

Principles of chemotherapy. Ann De Becker Klinische Hematologie UZ Brussel

MABCAMPATH mg 3 INJ GENZYME BIOPHARMACEUTICALS. MABCAMPBATH mg 3 INJ GENZYME BIOPHARMACEUTICALS

H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS

DRUGS YOU NEED TO KNOW

APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer

Cancer Drugs CANCER DRUGS NEW DRUGS AND INDICATIONS OVER THE PAST TEN YEARS

CANCER CHEMOTHERAPY Michael Lea

Chemotherapy Agents 101

2. Date of most recent breast cancer diagnosis / / 3. Pathlogy: Padget s Phyllodes Tubular Medullary Mucinous

Subject: Palonosetron Hydrochloride (Aloxi )

4. Shown below is the structure of doxorubicin (Adriamycin). What is true about this agent?

Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients

See Important Reminder at the end of this policy for important regulatory and legal information.

ORAL ONCOLOGY CRITERIA

Cancer drug approvals for paediatric indications (n=43)

Guidelines for the Use of Anti-Emetics with Chemotherapy

Guideline Update on Antiemetics

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER

REGULATORY INFORMATION

CancerPACT Cancer Patients Alliance for Clinical Trials

Year III Pharm D. Dr. V. Chitra

OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY)

CancerPACT Cancer Patients Alliance for Clinical Trials

See Important Reminder at the end of this policy for important regulatory and legal information.

Part B payment for drugs in Medicare 0

Introduction to Targeted Therapy

Subject: Fosnetupitant-Palonosetron (Akynzeo) IV

Part B payment for drugs in Medicare 0

Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives

Targeted Medicine and Molecular Therapeutics. Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009

Cancer Chemotherapy. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018

Working Formulary January 2013 Oncology Chemotherapy Regimens

See Important Reminder at the end of this policy for important regulatory and legal information.

ORAL ONCOLOGY CRITERIA

Antineoplastic Drugs. Antineoplastic Drugs. Herbal Alert. Pharmacology Chapter 51. Green tea

Chapter 2 Clinical Anticancer Drugs for Cancer Treatment

See Important Reminder at the end of this policy for important regulatory and legal information.

Leukemia. Treatment of. compendia. Associated ICD-9-CM Codes: Drug & Administration. managedcareoncology.com

Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care

Targeted Therapy Vijay Narang

Clinical Policy: Lapatinib (Tykerb) Reference Number: CP.PHAR.79 Effective Date: Last Review Date: 11.17

Drug-targeted therapies and Predictive Prognosis: Changing Role for the Pathologist

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017

National Cancer Drugs Fund List - Approved

CHEMOTHERAPY/ ANTICANCER DRUGS/ NEOPLASTIC AGENTS

Transcription:

Chemotherapy 101 for Radiation Oncology Workers James Sinclair, M.D. CCARE/Medical Director Scripps Cancer Center March 9, 2013

Category 1) Alkylating agents Alkylating agents directly damage DNA to prevent the cancer cell from reproducing. As a class of drugs, these agents are not phase-specific; in other words, they work in all phases of the cell cycle. Alkylating agents are used to treat many different cancers, including leukemia, lymphoma, Hodgkin disease, multiple myeloma, and sarcoma, as well as cancers of the lung, breast, and ovary. Because these drugs damage DNA, they can cause long-term damage to the bone marrow. In rare cases, this can eventually lead to acute leukemia. The risk of leukemia from alkylating agents is dose-dependent, meaning that the risk is small with lower doses, but goes up as the total amount of the drug used gets higher. The risk of leukemia after getting alkylating agents is highest about 5 to 10 years after treatment.

There are different classes of alkylating agents, including: Nitrogen mustards: such as mechlorethamine (nitrogen mustard)- Hodgkins Disease chlorambucil, cyclophosphamide (Cytoxan ), Ifosfamide (Ifex) Sarcoma Bendamustine (Treanda) melphalan Nitrosoureas: streptozocin carmustine (BCNU) Triazines: dacarbazine (DTIC) Temozolomide (Temodar ) Lymphoma Myeloma Islet Cell Cancer Brain Cancer Melanoma Brain Cancer Ethylenimines: thiotepa and altretamine (hexamethylmelamine) Ovarian Cancer

Category 2) The platinum drugs Cisplatin Testis and Lung Cancer carboplatin-lung, Ovary, Breast Cancer Oxalaplatin- Colon Cancer are sometimes grouped with alkylating agents because they kill cells in a similar way. These drugs are less likely than the alkylating agents to cause leukemia later on. They have significant toxicity including nausea, vomiting, neuropathy, and renal toxicity

Category 3) Antimetabolites Antimetabolites are a class of drugs that interfere with DNA and RNA growth by substituting for the normal building blocks of RNA and DNA. These agents damage cells during the S phase. They are commonly used to treat leukemias, cancers of the breast, ovary, and the intestinal tract, as well as other types of cancer.

Examples of antimetabolites include: 5-fluorouracil (5-FU) 6-mercaptopurine (6-MP) Capecitabine (Xeloda ) Cladribine (2CDA) Cytarabine (Ara-C ) Fludarabine (Fludara) Gemcitabine (Gemzar ) Hydroxyurea (Hydrea) Methotrexate Pemetrexed (Alimta ) Colon Leukemia Colon Cancer Hairy Cell Leukemia Leukemia Lymphoma Pancreas Cancer Leukemia Trophoblastic Disease Lung Cancer

Category 4) Anti-tumor antibiotics Anthracyclines Anthracyclines are anti-tumor antibiotics that interfere with enzymes involved in DNA replication. These drugs work in all phases of the cell cycle. They are widely used for a variety of cancers. A major consideration when giving these drugs is that they can permanently damage the heart if given in high doses. For this reason, lifetime dose limits are often placed on these drugs.

Examples of anthracyclines include: Daunorubicin (Daunoxome) Doxorubicin (Adriamycin ) Epirubicin (Ellence) Idarubicin (Idamycin) Leukemia Breast Cancer Breast Cancer Leukemia

Other anti-tumor antibiotics: Anti-tumor antibiotics that are not anthracyclines include: Actinomycin-D Bleomycin Doxil (liposomal doxorubicin) Mitomycin-C Sarcoma Testis Cancer Ovarian Cancer Anal Cancer Mitoxantrone is an anti-tumor antibiotic that is similar to doxorubicin in many ways, including the potential for damaging the heart. This drug also acts as a topoisomerase II inhibitor and can lead to treatment-related leukemia. Mitoxantrone is used to treat prostate cancer, breast cancer, lymphoma, and leukemia.

Category 5) Topoisomerase inhibitors These drugs interfere with enzymes called topoisomerases, which help separate the strands of DNA so they can be copied. They are used to treat certain leukemias, as well as lung, ovarian, gastrointestinal, and other cancers.

Examples of topoisomerase I inhibitors include: topotecan (Hycamtin) Ovarian Cancer irinotecan (Camptosar) Colon Cancer Examples of topoisomerase II inhibitors include: etoposide (Vepesid) Testis Cancer teniposide Mitoxantrone also inhibits topoisomerase II. Treatment with topoisomerase II inhibitors increases the risk of a second cancer acute myelogenous leukemia (AML). With this type of drug, a secondary leukemia can be seen as early as 2 to 3 years after the drug is given.

Category 6) Mitotic inhibitors Mitotic inhibitors are often plant alkaloids and other compounds derived from natural products. They can stop mitosis or inhibit enzymes from making proteins needed for cell reproduction. These drugs work during the M phase of the cell cycle but can damage cells in all phases. They are used to treat many different types of cancer including breast, lung, myelomas, lymphomas, and leukemias. These drugs are known for their potential to cause peripheral nerve damage, which can be a dose-limiting side effect.

Examples of mitotic inhibitors include: Taxanes: paclitaxel (Taxol ) docetaxel (Taxotere ) Abraxane (nano particle albumin bound-taxol) Epothilones: ixabepilone (Ixempra ) Vinca alkaloids: vinblastine (Velban ) vincristine (Oncovin ) vinorelbine (Navelbine ) Estramustine (Emcyt ) Breast Cancer Hodgkins Disease, Hodgkins Disease, Breast Cancer Prostate Cancer

Category 7) Corticosteroids Steroids are natural hormones and hormone-like drugs that are useful in treating some types of cancer (lymphoma, leukemias, and multiple myeloma), as well as other illnesses. When these drugs are used to kill cancer cells or slow their growth, they are considered chemotherapy drugs. Corticosteroids are also commonly used as anti-emetics to help prevent nausea and vomiting caused by chemotherapy. They are used before chemotherapy to help prevent severe allergic reactions (hypersensitivity reactions), too. When a corticosteroid is used to prevent vomiting or allergic reactions, it s not considered chemotherapy. Examples include prednisone, methylprednisolone (Solumedrol ), and dexamethasone (Decadron ).

Category 8) Differentiating agents: These drugs act on the cancer cells to make them mature into normal cells. Examples include : tretinoin (ATRA or Atralin ) bexarotene (Targretin ) arsenic trioxide (Arsenox ) M3 AML T cell Lymphoma M3 AML

Category 9) Hormone therapy Drugs in this category are sex hormones, or hormone-like drugs, that change the action or production of female or male hormones. They are used to slow the growth of breast, prostate, and endometrial (uterine) cancers, which normally grow in response to natural hormones in the body. These cancer treatment hormones do not work in the same ways as standard chemotherapy drugs, but rather by preventing the cancer cell from using the hormone it needs to grow, or by preventing the body from making the hormones.

Examples include: The anti-estrogens for Breast Cancer: fulvestrant (Faslodex ) tamoxifen toremifene (Fareston ) Aromatase inhibitors: anastrozole (Arimidex ) exemestane (Aromasin ) letrozole (Femara ) Progestins: megestrol acetate (Megace )

Anti-androgens for Prostate Cancer: bicalutamide (Casodex ) flutamide (Eulexin ) nilutamde (Nilandron ) abiraterone (Zytiga) enzalutamide (Xtandi) Gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone-releasing hormone (LHRH) agonists or analogs: leuprolide (Lupron ) goserelin (Zoladex ) Triptorelin (Trelstar)

Category 10) Immunotherapy Some drugs are given to people with cancer to stimulate their natural immune systems to recognize and attack cancer cells. These drugs offer a unique method of treatment, and are often considered to be separate from chemotherapy. There are different types of immunotherapy. Active immunotherapies stimulate the body s own immune system to fight the disease. Passive immunotherapies do not rely on the body to attack the disease; instead, they use immune system components (such as antibodies) created outside the body.

Types of immunotherapies and some examples include: Monoclonal antibody therapy (passive immunotherapies), such as: rituximab (Rituxan ) Lymphoma alemtuzumab (Campath ) Leukemia Arzerra Leukemia Actemra Hodgkins Disease Non-specific immunotherapies and adjuvants (other substances or cells that boost the immune response), such as BCG, interleukin-2 (IL-2), and interferon-alfa Cancer vaccines (active specific immunotherapies). In 2010, the FDA approved the first vaccine to treat cancer (the Provenge vaccine for advanced prostate cancer);

Yervoy (Ipilimumab) Melanoma MDX-101 is a monoclonal antibody that turns off the inhibition of circulating cytotoxic T lymphocytes

Tositumomab (Bexxar) Ibritumomab tiuxetan (Zevalin) Monoclonal antibodies used to deliver radiation in the form of Yttrium-90 to the lymphoma.

Monoclonal antibodies are substances that are made in the laboratory by hybridoma technology to block a specific target on the outside of cancer cells. These drugs are usually given intravenously (IV) because they are large compounds that are not absorbed well by the body. Examples include: bevacizumab (Avastin) ziv-aflibercept (Zaltrap) cetuximab (Erbitux) panitumumab (Vectibix) pertuzumab (Perjeta) trastuzumab (Herceptin) Trastuzumab emtansine (Kadcyla) Colon Cancer Colon Ca Colon Ca Colon Ca Breast Ca Breast Ca Breast Ca

Oral small molecules are given in the form of a pill that a patient takes by mouth because the body absorbs them better than monoclonal antibodies. These drugs usually block cancer processes in the inside of a cancer cell. Examples include Tyrosine Kinase Inhibitors: dasatinib (Sprycel) erlotinib (Tarceva) gefitinib (Iressa) imatinib (Gleevec) nilotinib (Tasigna) sorafenib (Nexavar) sunitinib (Sutent) bosutinib (Bosulif) axitinib (Inlyta) regorafinib (Stivarga) pazopanib (Votrient) crizotinib (Xalkori) Vemurafenib(Zelboraf) CML Lung Ca Lung Ca CML CML Kidney Ca Kidney Ca CML Kidney Ca Colon Ca Kidney Ca Lung Ca Melanoma

MTOR inhibitor/mammalian target of rapamicin a Serine threonine kinase inhibitor everolimus (Afinitor) Temsirolimus (Toricel) Kidney Cancer Kidney Cancer

Proteasome inhibitors interfere with specialized proteins called enzymes that break down other proteins in the cell. Used primarily in Multiple Myeloma: bortezomib (Velcade) carfilzomib (Kyprolis)

Inhibition of DNA methyltransferase: Decitabine (Dacogen) Azacitidine (Vidaza) Myelodysplasia Myelodysplasia

Immunomodulator/Antiangiogenesis used primarily in Multiple Myeloma Thalidomide (Thalomid) Lenalidomide (Revlimid) Pamolidomide (Pomalyst)

Into the impossible with a father of string theory After abandoning family plans to go into the heating business, he went on to become a founder of string theory. Now Leonard Susskind is teaching physics to people in their 90s. Physics is a very human enterprise, and the process of going from the human, the contentious, to the objective kernel of truth - textbook science - requires input from experiment. What's going to happen when that becomes prohibitive?